Cyclooxygeanse-2 promotes XXXX in @entity421 .

@entity1 @entity5 @entity421 @entity3 @entity105 @entity3840
@entity3840 ( @entity3840 ), an inducible form of the enzyme that catalyzes the first step in the synthesis of prostanoids, is associated with @entity105 , which is suspected to promote angiogenesis and tissue invasion of @entity5 and resistance to apoptosis. @entity3840 is also involved in @entity3 and poor prognosis of @entity5 . @entity421 with @entity3840 positivity is from 67 to 92  %. @entity3840 -positive rate in metastatic lesions was greater than that of biopsy and/or resected samples of the primary site in @entity421 . And, what role does @entity3840 play in @entity3 ? Genetic studies support a cause-effect connection between @entity3840 and tumorigenesis. @entity3840 expression had a poor prognosis with regard to @entity3 , and @entity1 with increased @entity3840 expression in lung metastases died of the disease. @entity3840 expression has also been established as a marker in @entity1 @entity421 , and @entity3840 inhibition has been suggested as a possible way of improving therapeutic outcome. In addition, COX-inhibitors inhibit the @entity5 initiation, matrix metalloproteinases (MMPs), cell differentiation and T cell proliferation and suppression of the antitumor activity of natural killer cells and macrophages, angiogenic mechanism. Therefore, we can exert the COX-inhibitors to potentialize the effects of chemotherapeutic agents, and reverse the @entity3 in @entity421 to facilitate the @entity1 who may benefit from addition of COX-inhibitors to standard cytotoxic therapy.
